AIRLINK 63.78 Increased By ▲ 1.58 (2.54%)
BOP 6.14 Decreased By ▼ -0.09 (-1.44%)
CNERGY 4.87 Decreased By ▼ -0.12 (-2.4%)
DFML 14.94 Increased By ▲ 0.04 (0.27%)
DGKC 66.99 Decreased By ▼ -2.00 (-2.9%)
FCCL 17.39 Decreased By ▼ -0.34 (-1.92%)
FFBL 24.93 Increased By ▲ 0.33 (1.34%)
FFL 9.18 Decreased By ▼ -0.03 (-0.33%)
GGL 10.23 Increased By ▲ 0.33 (3.33%)
HBL 108.24 Decreased By ▼ -0.26 (-0.24%)
HUBC 116.75 Increased By ▲ 0.25 (0.21%)
HUMNL 6.63 Decreased By ▼ -0.07 (-1.04%)
KEL 4.41 Decreased By ▼ -0.05 (-1.12%)
KOSM 4.65 Decreased By ▼ -0.07 (-1.48%)
MLCF 35.87 Decreased By ▼ -1.03 (-2.79%)
OGDC 123.07 Decreased By ▼ -0.23 (-0.19%)
PAEL 22.94 Increased By ▲ 0.50 (2.23%)
PIAA 23.89 Increased By ▲ 1.67 (7.52%)
PIBTL 5.77 Increased By ▲ 0.02 (0.35%)
PPL 111.09 Increased By ▲ 0.19 (0.17%)
PRL 27.60 Increased By ▲ 0.03 (0.11%)
PTC 15.25 Increased By ▲ 1.06 (7.47%)
SEARL 53.02 Decreased By ▼ -0.23 (-0.43%)
SNGP 63.34 Decreased By ▼ -0.41 (-0.64%)
SSGC 10.83 Decreased By ▼ -0.17 (-1.55%)
TELE 9.23 Increased By ▲ 0.28 (3.13%)
TPLP 10.97 Increased By ▲ 0.24 (2.24%)
TRG 71.43 Increased By ▲ 1.13 (1.61%)
UNITY 25.00 Increased By ▲ 0.80 (3.31%)
WTL 1.38 Increased By ▲ 0.02 (1.47%)
BR100 6,751 Increased By 52.9 (0.79%)
BR30 22,646 Increased By 28.2 (0.12%)
KSE100 65,503 Increased By 612.1 (0.94%)
KSE30 21,721 Increased By 185.1 (0.86%)

British drugmaker GSK said on Tuesday its antibody-based COVID-19 therapy with US partner Vir Biotechnology is effective against all mutations of the new Omicron coronavirus variant, citing new data from early-stage studies.

The data, yet to be published in a peer-reviewed medical journal, shows that the companies' treatment, sotrovimab, is effective against all 37 identified mutations to date in the spike protein, GSK said in a statement.

Last week, another pre-clinical data showed that the drug had worked against key mutations of the Omicron variant. Sotrovimab is designed to latch on to the spike protein on the surface of the coronavirus, but Omicron has been found to have an unusually high number of mutations on that protein.

UK approves GSK Covid drug, appears effective against Omicron

"These pre-clinical data demonstrate the potential for our monoclonal antibody to be effective against the latest variant, Omicron, plus all other variants of concern defined to date by the WHO," GSK Chief Scientific Officer Hal Barron said.

GSK and Vir have been engineering so-called pseudoviruses that feature major coronavirus mutations across all suspicious variants that have emerged so far, and have run lab tests on their vulnerability to sotrovimab treatment.

Comments

Comments are closed.